AIAI News1h ago
Insilico Medicine advances AI drug for IPF to Phase III trials
Insilico Medicine is advancing to Phase III human trials for testing a drug identified by AI targeting idiopathic pulmonary fibrosis (IPF). This progression supplies the computational drug discovery sector with empirical test cases, advancing an AI medicine past early safety…
Read full articleSource: AI News · Opens in new tab